Market Place
Sourcing Support
Genenta, AGC Biologics Strengthen Cell Therapy Manufacturing Pact
09 Jan 2025 //
CONTRACTPHARMA
Genenta Secures Approval for Trial in Metastatic Renal Cell Cancer
02 Oct 2024 //
GLOBENEWSWIRE
Genenta Welcomes New Directors Cantello, Chung, Sharei, Wider
06 May 2024 //
GLOBENEWSWIRE
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM
08 Feb 2024 //
GLOBENEWSWIRE
Genenta to Present at Upcoming Scientific and Investor Conferences
06 Sep 2023 //
GLOBENEWSWIRE
Genenta Announces Trial Progress & Proposed Expansion in Solid Tumor Treatments
28 Jul 2023 //
GLOBENEWSWIRE
European Commission Grants Orphan Drug Designation to Temferon for Glioma
29 Jun 2023 //
ONCLIVE
Genenta to Provide Update on Lead Product Temferon
16 May 2023 //
GLOBENEWSWIRE
Genenta Announces Extension of Agreement with Ospedale San Raffaele
03 Apr 2023 //
GLOBENEWSWIRE
FDA Grants Orphan Drug Designation to Temferon for Glioblastoma Multiforme
02 Mar 2023 //
GLOBENEWSWIRE
Genenta and AGC Biologics Enter Development and Manufacturing Service Agreement
07 Feb 2023 //
GLOBENEWSWIRE
Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune Temferon™
07 Nov 2022 //
GLOBENEWSWIRE
Genenta Provides First Half 2022 Business Update and Financial Results
24 Oct 2022 //
GLOBENEWSWIRE
Genenta to Present at Upcoming Scientific and Investor Conferences
05 Oct 2022 //
GLOBENEWSWIRE
AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative
25 Jul 2022 //
GLOBENEWSWIRE
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
13 May 2022 //
GLOBENEWSWIRE
Genenta Appoints Industry Veteran Tim Obara as Head of Business Development
09 May 2022 //
GLOBENEWSWIRE
Genenta Progresses to Higher Dosing Cohort in Temferon PI/IIa Trial in GM
04 May 2022 //
GLOBENEWSWIRE
Genenta ASGCT Clinical Data Highlights Temferon Biological Effects in Glioma
02 May 2022 //
GLOBENEWSWIRE
Genenta Announces Nomination of Mark A. Sirgo as Chair
27 Apr 2022 //
GLOBENEWSWIRE
Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy
20 Apr 2022 //
GLOBENEWSWIRE
Genenta Data at AACR to Describe On-Target Biological Activity of Temferon
09 Mar 2022 //
GLOBENEWSWIRE
Genenta to Participate at Upcoming Investor Conferences
24 Feb 2022 //
GLOBENEWSWIRE
Genenta Closes Its Upsized Initial Public Offering of American Depository Shares
17 Dec 2021 //
GLOBENEWSWIRE
Genenta Announces Pricing of Upsized Initial Public Offering
15 Dec 2021 //
GLOBENEWSWIRE
Genenta Announces Pricing of Upsized Initial Public Offering
14 Dec 2021 //
GLOBENEWSWIRE
Genenta To Present Updated Phase I/II Data At Upcoming Scientific SNO AND ASH
16 Nov 2021 //
GLOBENEWSWIRE
Genenta is attempting a rare biotech leap from Milan to Wall Street
11 Nov 2021 //
ENDPTS
Italian solid tumor biotech Genenta Science files for a $35 million US IPO
10 Nov 2021 //
RENAISSANCECAPITAL
Genenta Announces Filing of Registration Statement for Proposed IPO
10 Nov 2021 //
GLOBENEWSWIRE
Genenta Phase I/II Glioblastoma Data at ASGCT Show Temferon™
14 May 2021 //
GLOBENEWSWIRE
